Final recommendations issued Sept. 28 from the Heart Rhythm Society are aimed at providing heart patients with clearer ...

Researchers in The Netherlands say they’ve realized the dream of truly interactive 3-D medical imaging: A company called Crosslinks is working to develop and market a software invention in Europe and around the world that provides 3-D visualization that clinicians and researchers can not only view head-on, but actually walk around and through.

Johnson & Johnson has filed a $5.5 billion lawsuit against Guidant Corp. in U.S. District Court in New York, claiming that Guidant leaked confidential information to Abbott Laboratories to secure a crucial component of the deal with Boston Scientific, reports Modernhealthcare.com.

Drugs traditionally used for the treatment of gastric ulcers could have therapeutic potential in chronic heart failure, according to new research coming out of Japan. One outcome showed that famotidine appears to reduce left ventricular end-diastolic (LVD-d) and end-systolic (LVD) lengths and reduce BNP (B-type natriuretic peptide) levels.

IMV ServiceTrak ranked GE Healthcare No. 1 for CT and MR Service in a comparison against five other manufacturers of the ...

Enrollment is complete for a landmark study designed to increase clinical understanding of vulnerable plaque, the deadly, lipid-rich coronary plaque that ruptures without warning or symptoms and possibly the source of most heart attacks.

Positive six-month results of Abbott's SPIRIT II clinical trial of the XIENCE V Everolimus Eluting Coronary Stent System were presented at the World Congress of Cardiology conference in Barcelona, Spain. XIENCE V, which has received CE Mark approval, is currently an investigational device in the U.S. and Japan — Abbott says it plans to initiate European launch of the coronary DES in October.